Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of confirmed active severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection from any respiratory specimen collected ≤7 days from when the first dose of study treatment was expected to be taken.~* Experienced at least one of the following SARS-CoV-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-COVID-19 health status):~  * Fever (can be subjective) or feeling feverish~ * Cough~ * Shortness of breath or difficulty breathing at rest or with exertion~ * Sore throat~ * Body pain or muscle pain~ * Fatigue~ * Headache~* Agreed to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest.~* Agreed to not obtain study medications outside of the A5395 study.~Exclusion Criteria:~* Need for hospitalization or immediate medical attention in the clinical opinion of the study investigator.~* History of or current hospitalization for COVID-19.~* History of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry.~* Personal or family history of Long QT syndrome.~* History of kidney disease.~* History of ischemic or structural heart disease.~* History of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation~* Personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (G6PD) deficiency.~* Used drugs with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis.~* Requirement or expected requirement for a medication that significantly prolongs QT intervals or increases risk for QT prolongation.~* Loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry.~* Participated in a study where co-enrollment was not allowed.~* Receipt of a SARS-CoV-2 vaccination prior to study entry.~* Known allergy/sensitivity or any hypersensitivity to components of HCQ, azithromycin, or their formulation.~* More than 10 days of any of the following symptoms attributed to the SARS-CoV-2 infection at study entry:~  * Fever (can be subjective) or feeling feverish~ * Cough~ * Shortness of breath or difficulty breathing at rest or with exertion~ * Sore throat~ * Body pain or muscle pain~ * Fatigue~ * Headache~ * Chills~ * Nasal obstruction or congestion~ * Loss of taste or smell~ * Nausea or vomiting~ * Diarrhea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro) (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days).
- Arm B: Placebo for Hydroxychloroquine and Azithromycin (Type: PLACEBO_COMPARATOR): Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues